VYNE Therapeutics Inc. (VYNE)
- Previous Close
1.2500 - Open
1.2600 - Bid 1.1800 x 100
- Ask 1.2600 x 100
- Day's Range
1.2100 - 1.2699 - 52 Week Range
1.1800 - 4.3000 - Volume
101,031 - Avg. Volume
171,474 - Market Cap (intraday)
20.331M - Beta (5Y Monthly) 1.77
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9800 - Earnings Date Aug 12, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.38
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
vynetherapeutics.comRecent News: VYNE
View MorePerformance Overview: VYNE
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VYNE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VYNE
View MoreValuation Measures
Market Cap
20.33M
Enterprise Value
-29.88M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
85.93
Price/Book (mrq)
0.46
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.37%
Return on Equity (ttm)
-66.15%
Revenue (ttm)
605k
Net Income Avi to Common (ttm)
-42.17M
Diluted EPS (ttm)
-0.9800
Balance Sheet and Cash Flow
Total Cash (mrq)
50.27M
Total Debt/Equity (mrq)
0.14%
Levered Free Cash Flow (ttm)
--